ANDA 204659, held by Strides Pharma International. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 204659 (Methylphenidate Hydrochloride), held by Strides Pharma International, was first approved by FDA on Jul 15, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2019 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride36MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride54MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Apr 1, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 15, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters